Q2 2025 Management View Eric M. Dube, President and CEO, described Q2 2025 as "a standout for Travere, a reflection of strong ...

LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported second quarter 2025 financial and ...

Q2 2025 Earnings Call Transcript August 6, 2025 Travere Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the ...

Investing.com -- Travere Therapeutics, Inc. (NASDAQ: TVTX) reported stronger-than-expected second quarter 2025 financial results on Wednesday, driven by significant growth in FILSPARI sales, sending ...

Get insights from Ligand Pharmaceuticals' Q2 2025 earnings—57% royalty revenue growth, raised guidance, and key partnerships driving long-term growth.

Ligand Pharmaceuticals (NASDAQ:LGND), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7 ...